A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Takeda
- 02 Feb 2018 Planned End Date changed from 28 Feb 2019 to 4 Sep 2019.
- 02 Feb 2018 Planned primary completion date changed from 28 Feb 2019 to 4 Sep 2019.
- 25 Aug 2017 Status changed from recruiting to active, no longer recruiting.